The director of the Office of Technology Transfer at the US National Institutes of Health has stressed that the OTT will be negotiating "very tough agreements" with companies on licensing agreements, and that she is currently restructuring the Office to put in "a very strong monitoring arm" to look after these agreements.
Maria Freire said that the milestones which the Office would be using to monitor licensing agreements would cover not only royalties and economics, but also, in cases where this is appropriate, public access. Under the reorganization, she added, two employees will be working full-time on monitoring license agreements, with one in the area of cellular growth and regulation and the other in disease management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze